Zoetis Inc. $ZTS Stock Position Lowered by Fishman Jay A Ltd. MI

Fishman Jay A Ltd. MI lessened its stake in Zoetis Inc. (NYSE:ZTS) by 85.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,496 shares of the company’s stock after selling 8,670 shares during the quarter. Fishman Jay A Ltd. MI’s holdings in Zoetis were worth $233,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Zoetis by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after buying an additional 189,287 shares during the period. Polen Capital Management LLC increased its stake in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock valued at $1,448,401,000 after buying an additional 1,313,653 shares during the period. Northern Trust Corp increased its stake in Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock valued at $1,071,032,000 after buying an additional 78,508 shares during the period. Goldman Sachs Group Inc. increased its stake in Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after buying an additional 109,791 shares during the period. Finally, Brown Advisory Inc. increased its stake in Zoetis by 7.6% in the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock valued at $725,866,000 after buying an additional 312,746 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $146.45 on Monday. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The company has a fifty day simple moving average of $149.79 and a 200 day simple moving average of $155.02. The company has a market cap of $64.91 billion, a P/E ratio of 25.21, a P/E/G ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $196.55.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. Zoetis’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on ZTS. Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and decreased their target price for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Saturday, September 27th. Finally, Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.